← All trials
NCT03289520
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 7, 2003
- Primary completion
- Jun 18, 2007
- Completion date
- Jun 18, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 877
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- National Institutes of Health (NIH)Study director
- National Institutes of Health (NIH)Study director
- Boston UniversityCollaborator
- CAMC Health SystemCollaborator
- Duke UniversityCollaborator
- Emory UniversityCollaborator
- University of IowaCollaborator
- St. Louis UniversityCollaborator
- Vanderbilt UniversityCollaborator
- University of MassachusettsCollaborator
- University of Alabama, BirminghamCollaborator
- Washington University in St. LouisCollaborator
- Tyler Nephrology AssociatesCollaborator
- Vascular Surgery Associates LLCCollaborator
- The Cleveland ClinicCollaborator
- The University of Texas, DallasCollaborator
- MaineGeneral HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.